Goldman Sachs’s Arcellx ACLX Stock Holding History

Goldman Sachs’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.21M	Buy	28,000 +6,800	+32%	+$600K	﹤0.01%	4112
2025 Q4	$1.38M	Buy	+21,200	New	+$1.69M	﹤0.01%	4888

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Goldman Sachs's ACLX Position: Q1 2026 in Review

Goldman Sachs increased its Arcellx (ACLX) stake by 96% in Q1 2026, buying an estimated $56.8M and bringing the position to 1,312,155 shares worth $151M. The position accounts for 0.02% of the portfolio, ranked #820.

Goldman Sachs first reported a position in ACLX in Q1 2022 and has held it in 16 quarters since. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

Goldman Sachs held 1,312,155 shares of Arcellx worth $151M as of Q1 2026.
Goldman Sachs bought 643,675 Arcellx shares in Q1 2026, an estimated $56.8M.
Arcellx made up 0.02% of Goldman Sachs's portfolio in Q1 2026, its #820 holding.
Goldman Sachs first reported a position in Arcellx in Q1 2022 and has held it in 16 quarters since.
239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.